 |
Adam Bonislawski is the editor of GenomeWeb's ProteoMonitor. He covers proteomics and life science mass spectrometry. E-mail Adam Bonislawski and follow his GenomeWeb Twitter account at @ProteoMonitor. |
Biodesix IDs Proteomic Signature for Predicting Response to GlobeImmune Pancreatic Cancer Therapy
June 29, 2012
Biodesix IDs Proteomic Signature for Predicting Response to GlobeImmune Pancreatic Cancer Therapy
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Biodesix Publishes Study Indicating Significant Influence of Veristrat on Doctor Treatment Decisions
April 5, 2013 / ProteoMonitor - Biodesix Inks Deal to Test Veristrat in Phase III Clinical Trial for Kadmon Lung Cancer Drug
March 2, 2012 / ProteoMonitor - Yale Researcher Suggests More Focus on EGFR Isoforms Needed in Development of Antibody-Based Drugs
May 20, 2011 / ProteoMonitor - Biodesix Raises $7.1M in Series C Financing Round
November 12, 2010 / ProteoMonitor - Proteomics Firms Net More than $8.75M in IRS Funds; Bulk of Awards Aimed at Diagnostics Work
November 5, 2010 / ProteoMonitor